Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Regeneron Pharmaceuticals
M.D. Anderson Cancer Center
Massachusetts General Hospital
Bayer
Boehringer Ingelheim
Seagen Inc.
Iovance Biotherapeutics, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Herlev and Gentofte Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Brown University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pierre Fabre Ltd
Bristol-Myers Squibb
OncoC4, Inc.
Bristol-Myers Squibb
Genmab
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Genmab
USWM, LLC (dba US WorldMeds)
Pfizer
Memorial Sloan Kettering Cancer Center
Pfizer
Wake Forest University Health Sciences
Iovance Biotherapeutics, Inc.
National Cancer Institute (NCI)
Pfizer
University of Pittsburgh
Bayer
iOnctura
Genentech, Inc.
UNICANCER
Dana-Farber Cancer Institute
AdventHealth Translational Research Institute
National Cancer Institute (NCI)